TCL Archive IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC March 28, 2014
TCL Archive Major Decisions On How NCI Will Spend Extra Money Won’t Be Made for Three-Four Months November 4, 1983